Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC RAHWAY, N.J., May 31, 2025--(BUSINESS ...

A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. It's a remarkable advance for patients who until recently faced dismal ...

Adding Keytruda to pre-surgical chemotherapy then giving it again after surgery improved event-free survival and pathologic complete response in patients with early-stage lung cancer. Adding Keytruda ...